Evidence Table 8

Quality assessment of randomized-controlled trials in patients with chronic pain

Internal Validity
Author, YearRandomization adequate?Allocation concealment adequate?Groups similar at baseline?Eligibility criteria specified?Outcome assessors masked?Care provider masked?Patient masked?Reporting of attrition, crossovers, adherence, and contaminationAttrition: differential/highIntention-to-treat (ITT) analysisQuality RatingFunding
Kimos, 2007YesYesNot reportedYesNot clear- main investigator maskedNot reportedYesYesNo. Non-completers:
24% (6/25) gabapentin
32% (8/25) placebo
88% of randomized subjects in ITT (48% drug, 40% placebo). Of these, 12% attended only 1st visit - no meds, no follow-up data.FairUniversity of Alberta Fund for Dentistry. Pharmascience donated gabapentin.
Muehlbacher, 2006NoNot reportedYesYesNot reportedYesYesYesNo. Non-completers:
4% (2/48) topiramate
10% (5/48) placebo
YesFair"The study was conducted independent of any institutional influence and was not funded"
Todorov, 2005Not reportedNoYesYesNoNoNoYes: attrition, aherence
No: crossover, contamination
22% (10/46) tiagabine
16% (7/45) gabapentin
NoPoorNot reported

From: Evidence Tables

Cover of Drug Class Review: Antiepileptic Drugs for Indications Other Than Epilepsy
Drug Class Review: Antiepileptic Drugs for Indications Other Than Epilepsy: Final Report Update 2 [Internet].
McDonagh M, Peterson K, Lee N, et al.
Portland (OR): Oregon Health & Science University; 2008 Oct.
Copyright © 2008, Oregon Health & Science University, Portland, Oregon.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.